Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Pathology

Building Your Care Team & Preparing for Visits

At a Glance

People with solitary fibrous tumor often benefit from review at a high-volume sarcoma center, where specialists can confirm the diagnosis, plan complex treatment, and coordinate long-term follow-up. Bring imaging, pathology materials, and complete medical records for review.

Because Solitary Fibrous Tumor (SFT) is exceptionally rare, research shows that it is often best managed at high-volume sarcoma centers, where multidisciplinary teams work together to plan complex surgeries and long-term care [1][2]. Seeking a second opinion on pathology and complex treatment decisions is common practice.

The Multidisciplinary Sarcoma Team

A “multidisciplinary” approach means that experts from different fields meet to discuss your specific case before any major treatment begins. This group, often called a sarcoma tumor board, ensures that all aspects of the tumor are considered [3][4].

Your core care team may include the following specialists, depending on your needs:

  • Expert Soft-Tissue Pathologist: A crucial member who confirms the STAT6 expression, identifies dedifferentiation, and evaluates the variables used in risk scoring [5][6].
  • Surgical Oncologist: A surgeon specialized in the specific area where your tumor is located (such as a thoracic surgeon for chest tumors or a neurosurgeon for brain/spine tumors) [7][8].
  • Medical Oncologist: Specializes in using systemic therapies like pazopanib if the tumor is advanced [9].
  • Radiation Oncologist: An expert in using targeted radiation for local control [10].
  • Endocrinologist: Essential if you have a history of or are at risk for Doege-Potter Syndrome (hypoglycemia) to manage glucose and hormone support.
  • Supportive Care: Oncology social workers, psycho-oncologists, or navigators who can assist with insurance, travel, scan anxiety, and coordinating care across facilities.

Preparing for Consultations and Second Opinions

When seeking an expert review or transferring care to a specialized center, gathering your medical history is vital. Fortunately, you do not always have to carry physical items yourself.

Checklist for Reviewing Your Records:

  1. Imaging: The specialists need to see the actual CT, MRI, or PET images, not just written reports. Ask the receiving center if they accept secure electronic transfers or if they require physical discs in DICOM format [11][12].
  2. Pathology Materials: The original H&E slides and immunohistochemistry (IHC) slides, and sometimes a tissue block, are needed. Usually, you should ask the originating pathology department to transfer these directly to the reviewing center to avoid mishandling these irreplaceable materials [6][13].
  3. Medical Records: Ensure the center has your full pathology report, operative notes, and any records of blood sugar issues or “episodes” that might suggest Doege-Potter Syndrome [14][15].

Shared Care Models

If you were diagnosed at a community hospital, a specialist review is highly recommended [2]. Because SFT requires long-term follow-up, getting the initial diagnosis and surgical plan right is critical [8].

Many patients find a “hybrid” or shared care model works best: they travel to the specialized center for complex surgery and major decision-making, but receive routine follow-up scans or systemic treatments at a hospital closer to home, with both teams staying in close communication [16]. Ask your center for a patient navigator who can help bridge this gap.

Common questions in this guide

Why might I need an SFT review at a sarcoma center?
Solitary fibrous tumor is rare, so a high-volume sarcoma center may offer more experience with complex surgery, pathology review, and long-term follow-up. A second opinion on the diagnosis or treatment plan is common and can help confirm that important decisions are based on a complete review of your case.
Which specialists may be involved in treating solitary fibrous tumor?
Your team may include a soft-tissue pathologist, surgical oncologist, medical oncologist, and radiation oncologist. A thoracic surgeon or neurosurgeon may be involved based on the tumor’s location, and an endocrinologist may help if low blood sugar suggests Doege-Potter Syndrome.
What should I send for an SFT second-opinion appointment?
Ask the center to obtain the actual CT, MRI, or PET images, preferably through a secure electronic transfer or in DICOM format, rather than only the written reports. The reviewing team may also need the original H&E and immunohistochemistry slides, sometimes a tissue block, plus your pathology report, operative notes, and records of low blood sugar episodes. The originating pathology department usually sends slides and tissue directly to help prevent loss or damage.
What does an SFT tumor board do?
A sarcoma tumor board is a meeting where specialists from several fields review your case before major treatment. It allows the team to consider the pathology, tumor location, surgery, radiation, medicines, and follow-up together instead of making each decision in isolation.
Why is a soft-tissue pathologist important for an SFT diagnosis?
A dedicated soft-tissue pathologist can confirm STAT6 expression and look for dedifferentiation and other features used to estimate tumor risk. Reviewing the original slides and, when needed, a tissue block can help ensure that the diagnosis and risk assessment are complete.
Can I have SFT care both at a specialist center and near home?
Often, a shared-care plan is possible when the specialist center and local hospital communicate clearly. The specialist center may handle complex surgery and major decisions, while the local team provides routine scans or systemic treatment closer to home, depending on your care plan.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many cases of Solitary Fibrous Tumor has this center managed in the last year?
  2. 2.Will my case be reviewed by a formal sarcoma tumor board, and which specialties are represented on that board?
  3. 3.Has a dedicated soft-tissue pathologist confirmed the STAT6 staining and risk-stratification variables like mitotic count?
  4. 4.Who will be the 'point person' coordinating my care between surgery, oncology, and radiology?
  5. 5.If my tumor is hypervascular, does the surgical team have experience with preoperative embolization?
  6. 6.Does the hospital have the intensive care resources needed to manage potential complications like Doege-Potter Syndrome or airway compression?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group.

    Annals of surgical oncology 2016; (23(11)):3531-3540 doi:10.1245/s10434-016-5336-7.

    PMID: 27480354
  2. 2

    Imaging in retroperitoneal soft tissue sarcoma.

    Messiou C, Morosi C

    Journal of surgical oncology 2018; (117(1)):25-32 doi:10.1002/jso.24891.

    PMID: 29193092
  3. 3

    Doege-Potter syndrome in a patient with solitary fibrous tumor of the retroperitoneum: a case report and literature review.

    Baheen Q, Tan M, Zhang B, et al.

    Discover oncology 2025; (16(1)):2077 doi:10.1007/s12672-025-03899-w.

    PMID: 41212425
  4. 4

    Malignant solitary fibrous tumor of the pancreas with systemic metastasis: A case report and review of the literature.

    Geng H, Ye Y, Jin Y, et al.

    World journal of clinical cases 2020; (8(2)):343-352 doi:10.12998/wjcc.v8.i2.343.

    PMID: 32047784
  5. 5

    The many faces of solitary fibrous tumor; diversity of histological features, differential diagnosis and role of molecular studies and surrogate markers in avoiding misdiagnosis and predicting the behavior.

    Tariq MU, Din NU, Abdul-Ghafar J, Park YK

    Diagnostic pathology 2021; (16(1)):32 doi:10.1186/s13000-021-01095-2.

    PMID: 33879215
  6. 6

    STAT6 Reliably Distinguishes Solitary Fibrous Tumors from Myofibromas.

    Smith MH, Islam NM, Bhattacharyya I, et al.

    Head and neck pathology 2018; (12(1)):110-117 doi:10.1007/s12105-017-0836-8.

    PMID: 28689369
  7. 7

    Case Report: Doege-Potter syndrome: a giant solitary fibrous pleural tumor causing severe hypoglycemia.

    De Vico C, Tappero C, Fontana E, et al.

    Frontiers in oncology 2025; (15()):1550343 doi:10.3389/fonc.2025.1550343.

    PMID: 40535137
  8. 8

    Liver Metastasis From Intracranial Hemangiopericytoma 8 Years After Initial Resection: Case Report.

    Hendrickson Rahmlow T, Kolagatla S, Mattingly K, et al.

    Journal of investigative medicine high impact case reports 2022; (10()):23247096221132244 doi:10.1177/23247096221132244.

    PMID: 36281561
  9. 9

    Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.

    Martin-Broto J, Stacchiotti S, Lopez-Pousa A, et al.

    The Lancet. Oncology 2019; (20(1)):134-144 doi:10.1016/S1470-2045(18)30676-4.

    PMID: 30578023
  10. 10

    Extrameningeal solitary fibrous tumors-surgery alone or surgery plus perioperative radiotherapy: A retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNet.

    Haas RL, Walraven I, Lecointe-Artzner E, et al.

    Cancer 2020; (126(13)):3002-3012 doi:10.1002/cncr.32911.

    PMID: 32315454
  11. 11

    A Case of Intracranial Solitary Fibrous Tumor/Hemangiopericytoma Repeatedly Misdiagnosed as Hypertensive Intracerebral Hemorrhage.

    Eom KS, Kim HS

    Brain tumor research and treatment 2020; (8(2)):113-118 doi:10.14791/btrt.2020.8.e13.

    PMID: 32648385
  12. 12

    Solitary Fibrous Tumors: 2016 Imaging Update.

    Keraliya AR, Tirumani SH, Shinagare AB, et al.

    Radiologic clinics of North America 2016; (54(3)):565-79.

    PMID: 27153789
  13. 13

    Solitary Fibrous Tumor of the Orbit: A Case Series With Clinicopathologic Correlation and Evaluation of STAT6 as a Diagnostic Marker.

    Blessing NW, Bermudez-Magner JA, Fernandez MP, et al.

    Ophthalmic plastic and reconstructive surgery 2020; (36(2)):164-171 doi:10.1097/IOP.0000000000001504.

    PMID: 31876648
  14. 14

    Doege-Potter syndrome associated to metastatic solitary fibrous tumor.

    Andrade MO, de Sousa NDC, do Amaral PS, et al.

    Autopsy & case reports 2022; (12()):e2021412 doi:10.4322/acr.2021.412.

    PMID: 36569984
  15. 15

    A challenging case of solitary fibrous tumor of the orbit in an anemic patient.

    Kumar SV, Madakshira MG, Kumar V, et al.

    Romanian journal of ophthalmology 2024; (68(4)):457-461 doi:10.22336/rjo.2024.82.

    PMID: 39936050
  16. 16

    Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

    von Mehren M, Kane JM, Agulnik M, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(7)):815-833 doi:10.6004/jnccn.2022.0035.

    PMID: 35830886

This page is for informational purposes only and does not constitute medical advice. A sarcoma specialist should interpret your records and help plan care for your specific situation.

Get notified when new evidence is published on Solitary Fibrous Tumor (SFT).

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.